Abstract
Obesity is a major risk factor for COVID-19 severity; however, the mechanisms underlying this relationship are not fully understood. Since obesity influences the plasma proteome, we sought to identify circulating proteins mediating the effects of obesity on COVID-19 severity in humans. Here, we screened 4,907 plasma proteins to identify proteins influenced by body mass index (BMI) using Mendelian randomization (MR). This yielded 1,216 proteins, whose effect on COVID-19 severity was assessed, again using MR. We found that a standard deviation increase in nephronectin (NPNT) was associated with increased odds of critically ill COVID-19 (OR = 1.71, P = 1.63 × 10−10). The effect was driven by an NPNT splice isoform. Mediation analyses supported NPNT as a mediator. In single-cell RNA-sequencing, NPNT was expressed in alveolar cells and fibroblasts of the lung in individuals who died of COVID-19. Finally, decreasing body fat mass and increasing fat-free mass were found to lower NPNT levels. These findings provide actionable insights into how obesity influences COVID-19 severity.
Competing Interest Statement
J.B.R. has served as an advisor to GlaxoSmithKline and Deerfield Capital. J.B.R.'s institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline, and Biogen for projects unrelated to this research. He is the CEO of 5 Prime Sciences (www.5primesciences.com), which provides research services for biotech, pharma, and venture capital companies for projects unrelated to this research. T.L. and V.F. are employees of 5 Prime Sciences. T.N. has received speaking fees from Boehringer Ingelheim and AstraZeneca regarding the projects unrelated to this research. The remaining authors declare no competing interests.
Funding Statement
The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825, 409511, 100558, 169303), the McGill Interdisciplinary Initiative in Infection and Immunity (MI4), the Lady Davis Institute of the Jewish General Hospital, the Jewish General Hospital Foundation, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK, Genome Québec, the Public Health Agency of Canada, McGill University, Cancer Research UK [grant number C18281/A29019] and the Fonds de Recherche Québec Santé (FRQS). J.B.R. is supported by an FRQS Mérite Clinical Research Scholarship. The support from Calcul Québec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. S.Y. is supported by the Japan Society for the Promotion of Science. T.L. is supported by a Vanier Canada Graduate Scholarship, an FRQS doctoral training fellowship, and a McGill University Faculty of Medicine Studentship. G.B.L. is supported by scholarships from the FRQS, the CIHR, and Québec's ministry of health and social services. Y.C. is supported by an FRQS doctoral training fellowship and the Lady Davis Institute/TD Bank Studentship Award. M.H. is supported by grants from the SciLifeLab/Knut and Alice Wallenberg national COVID-19 research program (M.H.: KAW 2020.0182, KAW 2020.0241), the Swedish Heart-Lung Foundation (M.H.: 20210089, 20190639, 20190637), and the Swedish Society of Medicine (M.H.:SLS-938101). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For summary-level data, all contributing cohorts obtained ethical approval from their intuitional ethics review boards. The contributing cohorts include: UK Biobank, GIANT consortium, deCODE study, FENLAND study, AGES Reykjavik study, INTERVAL study, COVID-19 Host Genetics Initiative, and BQC19. For individual-level data in BQC19, BQC19 received ethical approval from the Jewish General Hospital research ethics board (2020-2137) and the Centre hospitalier de l'Université de Montréal institutional ethics board (MP-02-2020-8929, 19.389).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Modified abstract, main text, and figures.
Data Availability
・GWAS summary statistics for each trait are available as follows: BMI (https://portals.broadinstitute.org/collaboration/giant/), Plasma proteome from the deCODE study (https://www.decode.com/summarydata/), COVID-19 outcomes (https://www.covid19hg.org/results/r7/), GTEx Portal V8 (https://gtexportal.org/home/datasets/). Plasma proteome from BQC19 (https://www.mcgill.ca/genepi/mcg-covid-19-biobank) Access to the data of BQC19 can be obtained upon approval of requests via bqc19.ca. ・Cis-pQTLs of each study are available in the corresponding publications' supplementary materials26-28 ・Body fat percentage, body fat mass, and fat-free mass GWASs are available at IEU OpenGWAS project with Accession ID of ukb-b-8909, ukb-b-19393, and ukb-b-13354, respectively (https://gwas.mrcieu.ac.uk/) ・Single-cell RNA-sequencing data of COVID-19 lung autopsy samples are available at the Single Cell Portal under the Accession ID of SCP1052 (https://singlecell.broadinstitute.org/single_cell/) ・CADD-scores v.1.6 can be accessed at https://cadd.gs.washington.edu/score ・Genotype data from 1000G genomes project is available at https://www.internationalgenome.org/data Code availability We used R v4.1.2 (https://www.r-project.org/), TwoSampleMR v.0.5.6 (https://mrcieu.github.io/TwoSampleMR/), snappy v1.0 (https://gitlab.com/richards-lab/vince.forgetta/snappy), coloc v5.1.0 (https://chr1swallace.github.io/coloc/), FINEMAP R package v1.4, Seurat v4.0.6 (https://satijalab.org/seurat/), PLINK v1.9 (http://pngu.mgh.harvard.edu/purcell/plink/), and GCTA fastGWA v1.93.3 (https://yanglab.westlake.edu.cn/software/gcta/). Custom codes are available on GitHub (https://github.com/satoshi-yoshiji/TwostepMR_obesity_COVID/).